Therapeutic Potential of Adipose-derived Stem Cells for Diabetic Foot Ulcers: a Systematic Review and Meta-analysis

Overview

Journal Diabetol Metab Syndr

Publisher Biomed Central

Specialty Endocrinology

Date 2025 Jan 8

PMID 39773633

Authors

Mohamed A Abu Elainein

Mohamad Mahmoud Whdan

Mahmoud Samir

Nada G Hamam

Mohamed Mansour

Mohamed Abdel Mohsen Mohamed

Mahmoud Mostafa Snosy

Mahmoud Ayman Othman

Ahmed Sayed Sobieh

Mahmoud Gamal Saad

Mohamed A Labna

Salma Allam

Affiliations

Soon will be listed here.

Abstract

Background: As the global prevalence of diabetes mellitus increases, the incidence of non-healing wounds in diabetic patients is expected to rise significantly, according to the International Diabetes Federation (IDF), around 537 million adults currently suffer from diabetes mellitus worldwide and 20% to 30% of individuals with diabetes are hospitalized due to diabetic foot ulcers. Conventional treatments such as traditional dressings often fall short in ensuring satisfactory wound healing, this Meta-analysis investigates the therapeutic potential of Adipose-derived Stem Cells (ADSCs) as a promising strategy for addressing this challenge.

Aims: To Assess the Therapeutic Potential of Adipose-Derived Stem Cells for Managing Diabetic Foot Ulcers compared to conventional lines of treatments.

Methods: The PubMed, SCOPUS, Web of Science Core Collection, Cochrane Library, and ClinicalTrials.gov. databases were searched from January 2000 and December 2023, articles were primarily evaluated regarding their titles and abstracts, then full-text screening was assessed against the inclusion and exclusion criteria by utilizing Rayyan software. The Cochrane risk of bias (RoB 2) assessment tool was used to identify the risk of bias in our included studies. A statistical analysis was performed using Review Manager (RevMan) Version 5 software. Dichotomous data was subjected to risk ratio analysis, while continuous data underwent Mean Difference (MD) evaluation, all was reported with 95% confidence intervals, P value is considered statistically significant if less than 0.05.

Results: Regarding the total healing state, five studies reported that more participants healed completely at the end of the follow-up period in the ADSCs group (Risk ratio = 1.56, 95% CI [1.32, 1.86], P < 0.00001), for the healing rate the overall effect estimate favors the ADSCs group (pooled effect estimate = 1.84, 95% CI [1.51, 2.89], P < 0.00001), and regarding the healing time the pooled mean difference of the studies demonstrated that the ADSCs group required fewer days to heal than the standard care group. (pooled mean difference = -19.33, 95% CI [-37.36, -1.29], P = 0.04).

Conclusion: ADSCs provide favorable healing results and safety compared to standard care for diabetic foot ulcers.

References

Nolan G, Smith O, Heavey S, Jell G, Mosahebi A . Histological analysis of fat grafting with platelet-rich plasma for diabetic foot ulcers-A randomised controlled trial. Int Wound J. 2021; 19(2):389-398. PMC: 8762540. DOI: 10.1111/iwj.13640. View

Armstrong D, Boulton A, Bus S . Diabetic Foot Ulcers and Their Recurrence. N Engl J Med. 2017; 376(24):2367-2375. DOI: 10.1056/NEJMra1615439. View

Schaper N, van Netten J, Apelqvist J, Bus S, Hinchliffe R, Lipsky B . Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes Metab Res Rev. 2020; 36 Suppl 1:e3266. DOI: 10.1002/dmrr.3266. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Yang L, Rong G, Wu Q . Diabetic foot ulcer: Challenges and future. World J Diabetes. 2022; 13(12):1014-1034. PMC: 9791573. DOI: 10.4239/wjd.v13.i12.1014. View

Smith O, Leigh R, Kanapathy M, Macneal P, Jell G, Hachach-Haram N . Fat grafting and platelet-rich plasma for the treatment of diabetic foot ulcers: A feasibility-randomised controlled trial. Int Wound J. 2020; 17(6):1578-1594. PMC: 7949265. DOI: 10.1111/iwj.13433. View

Uzun E, Guney A, Gonen Z, Ozkul Y, Kafadar I, Gunay M . Intralesional allogeneic adipose-derived stem cells application in chronic diabetic foot ulcer: Phase I/2 safety study. Foot Ankle Surg. 2020; 27(6):636-642. DOI: 10.1016/j.fas.2020.08.002. View

Thamm O, Eschborn J, Zimmermann L, Dekker C, Martin H, Brockmann M . Sublesional fat grafting leads to a temporary improvement of wound healing in chronic leg ulcers: A prospective, randomised clinical trial. Wound Repair Regen. 2023; 31(5):663-670. DOI: 10.1111/wrr.13111. View

Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y . Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019; 7(6):452-461. PMC: 8172050. DOI: 10.1016/S2213-8587(19)30093-2. View

De Angelis B, DAutilio M, Orlandi F, Pepe G, Garcovich S, Scioli M . Wound Healing: In Vitro and In Vivo Evaluation of a Bio-Functionalized Scaffold Based on Hyaluronic Acid and Platelet-Rich Plasma in Chronic Ulcers. J Clin Med. 2019; 8(9). PMC: 6780765. DOI: 10.3390/jcm8091486. View

10.

Perez-Favila A, Martinez-Fierro M, Rodriguez-Lazalde J, Cid-Baez M, Zamudio-Osuna M, Martinez-Blanco M . Current Therapeutic Strategies in Diabetic Foot Ulcers. Medicina (Kaunas). 2019; 55(11). PMC: 6915664. DOI: 10.3390/medicina55110714. View

11.

Gruber H, Somayaji S, Riley F, Hoelscher G, Norton H, Ingram J . Human adipose-derived mesenchymal stem cells: serial passaging, doubling time and cell senescence. Biotech Histochem. 2012; 87(4):303-11. DOI: 10.3109/10520295.2011.649785. View

12.

Jankovic S, Bogavac-Stanojevic N, Mikulic I, Izetbegovic S, Ilickovic I, Krajnovic D . A Questionnaire for Rating Health-related Quality of Life. Zdr Varst. 2021; 60(4):260-268. PMC: 8643113. DOI: 10.2478/sjph-2021-0035. View

13.

Gennai S, Leone N, Covic T, Migliari M, Lonardi R, Silingardi R . Health-related quality of life outcomes and hospitalization length of stay after micro-fragmented autologous adipose tissue injection in minor amputations for diabetic foot ulceration (MiFrAADiF Trial): results from a randomized controlled.... Int Angiol. 2021; 40(6):512-519. DOI: 10.23736/S0392-9590.21.04570-3. View

14.

Gentile P, Garcovich S . Concise Review: Adipose-Derived Stem Cells (ASCs) and Adipocyte-Secreted Exosomal microRNA (A-SE-miR) Modulate Cancer Growth and proMote Wound Repair. J Clin Med. 2019; 8(6). PMC: 6616456. DOI: 10.3390/jcm8060855. View

15.

Lonardi R, Leone N, Gennai S, Trevisi Borsari G, Covic T, Silingardi R . Autologous micro-fragmented adipose tissue for the treatment of diabetic foot minor amputations: a randomized controlled single-center clinical trial (MiFrAADiF). Stem Cell Res Ther. 2019; 10(1):223. PMC: 6664586. DOI: 10.1186/s13287-019-1328-4. View

16.

Moon K, Suh H, Kim K, Han S, Young K, Lee J . Potential of Allogeneic Adipose-Derived Stem Cell-Hydrogel Complex for Treating Diabetic Foot Ulcers. Diabetes. 2019; 68(4):837-846. DOI: 10.2337/db18-0699. View

17.

Tanios E, Ahmed T, Shafik E, Sherif M, Sayed D, Gaber N . Efficacy of adipose-derived stromal vascular fraction cells in the management of chronic ulcers: a randomized clinical trial. Regen Med. 2021; 16(11):975-988. DOI: 10.2217/rme-2020-0207. View

18.

Laucis N, Hays R, Bhattacharyya T . Scoring the SF-36 in Orthopaedics: A Brief Guide. J Bone Joint Surg Am. 2015; 97(19):1628-34. PMC: 5029523. DOI: 10.2106/JBJS.O.00030. View

19.

Frykberg R, Franks P, Edmonds M, Brantley J, Teot L, Wild T . A Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers: The TWO2 Study. Diabetes Care. 2019; 43(3):616-624. DOI: 10.2337/dc19-0476. View